Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment

Leukemia and Lymphoma

Volumn 55, Issue 8, 2014, Pages 1854-1860

  Lenglet, Julien ^a,b,c   Traullé, Catherine ^d   Mounier, Nicolas ^e   Benet, Claire ^a,b,c   Munoz Bongrand, Nicolas ^a   Amorin, Sandy ^a,b,c   Noguera, Maria Elena ^a   Traverse Glehen, Alexandra ^f   Ffrench, Martine ^f   Baseggio, Lucile ^d   Felman, Pascale ^d   Callet Bauchu, Evelyne ^d   Brice, Pauline ^a,b,c   Berger, Françoise ^f   Salles, Gilles ^d   Brière, Josette ^a,b,c   Coiffier, Bertrand ^d   Thieblemont, Catherine ^a,b,c  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d UNIVERSITÉ LYON 1   (France)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Splenectomy; Splenic marginal zone lymphoma; Treatment

Indexed keywords

AMOXICILLIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUDARABINE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; FEMALE; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SPLENECTOMY; SPLENIC MARGINAL ZONE LYMPHOMA; CANCER GRADING; CANCER STAGING; IMMUNOPHENOTYPING; LYMPHOMA, B-CELL, MARGINAL ZONE; MIDDLE AGED; MORTALITY; PROGNOSIS; RISK FACTOR; SPLENIC NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SPLENECTOMY; SPLENIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84904888953     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.861067     Document Type: Article

References (40)

1. Swerdlow S, Harris N, Jaff e E, et al. WHO classification of tumours of haematopoietic and lymphoid tissue. Lyon: IARC; 2008.
2. Thieblemont C, Felman P, Callet-Bauchu E, et al. Splenic marginalzone lymphoma: a distinct clinical and pathological entity. Lancet Oncol 2003; 4: 95-103.
3. Parry-Jones N, Matutes E, Gruszka-Westwood AM, et al. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol 2003; 120: 759-764.
4. Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma 2002; 3: 41-7.
5. Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006; 107: 4643-4649.
6. Dungarwalla M, Appiah-Cubi S, Kulkarni S, et al. High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis. Br J Haematol 2008; 143: 71-74.
7. Arcaini L, Paulli M, Boveri E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 2004; 100: 107-115.
8. Zibellini S, Capello D, Forconi F, et al. Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Haematologica 2010; 95: 1792-1796.
9. Callet-Bauchu E, Baseggio L, Felman P, et al. Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases. Leukemia 2005; 19: 1818-1823.
10. Gazzo S, Baseggio L, Coignet L, et al. Cytogenetic and molecular delineation of a region of chromosome 3q commonly gained in marginal zone B-cell lymphoma. Haematologica 2003; 88: 31-38.
11. Kiel MJ, Velusamy T, Betz BL, et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med 2012; 209: 1553-1565.
12. Rossi D, Trifonov V, Fangazio M, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med 2012; 209: 1537-1551.
13. Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 2008; 22: 487-495.
14. Arcaini L, Burcheri S, Rossi A, et al. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist 2006; 11: 285-291.
15. Chacon J, Mollejo M, Munoz E, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002; 100: 1648-1654.
16. Thieblemont C, Chettab K, Felman P, et al. Identification and validation of 7 genes, as potential markers, for the diff erential diagnosis of small B-cell lymphomas (lymphocytic B-cell lymphoma, marginal zone lymphoma, mantle cell lymphoma) by cDNA macroarrays analysis. Leukemia 2002; 16: 2326-2329.
17. Lefrere F, Hermine O, Belanger C, et al. Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia 2000; 14: 573-575.
18. Yasukawa M, Yamauchi H, Azuma T, et al. Dramatic efficacy of fludarabine in the treatment of an aggressive case of splenic lymphoma with villous lymphocytes. Eur J Haematol 2002; 69: 112-114.
19. Iannitto E, Minardi V, Calvaruso G, et al. Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes. Eur J Haematol 2005; 75: 130-135.
20. Cervetti G, Galimberti S, Sordi E, et al. Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol 2010; 21: 851-854.
21. Cheson B, Friedberg J, Kahl B, et al. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010; 10: 452-457.
22. Kalpadakis C, Pangalis GA, Dimopoulou MN, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 2007; 25: 127-131.
23. Tsimberidou A M, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006; 107: 125-135.
24. Bennett M, Sharma K, Yegena S, et al. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica 2005; 90: 856-858.
25. Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. Oncologist 2013; 18: 190-197.
26. Arcaini L, Orlandi E, Scotti M, et al. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. Clin Lymphoma 2004; 4: 250-252.
27. Else M, Marín-Niebla A, de la Cruz F, et al. R ituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol 2012; 159: 322-328.
28. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
29. Montalban C, Abraira V, Arcaini L, et al. Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. Leuk Lymphoma 2014; 55: 929-931.
30. Cheson B, Pfistner B, Juweid M, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
31. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
32. Iannitto E, Tripodo C. How I diagnose and treat splenic lymphomas. Blood 2011; 117: 2585-2595.
33. Baccarani U, Donini A, Terrosu G, et al. L aparoscopic splenectomy for haematological diseases: review of current concepts and opinions. Eur J Surg 1999; 165: 917-923.
34. Di Sabatino A, Carsetti R, Corazza G. Post-splenectomy and hyposplenic states. Lancet 2011; 378: 86-97.
35. Bisharat N, Omari H, Lavi I, et al. Risk of infection and death among post-splenectomy patients. J Infect 2001; 43: 182-186.
36. Holdsworth R, Irving A, Cuschieri A. Postsplenectomy sepsis and its mortality rate: actual versus perceived risks. Br J Surg 1991; 78: 1031-1038.
37. Waghorn D. Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. J Clin Pathol 2001; 54: 214-218.
38. Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d ' Hematologie Cellulaire (GFHC). Br J Haematol 1996; 93: 731-736.
39. Camacho FI, Mollejo M, Mateo MS, et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma - a description of a series of 12 cases. Am J Surg Pathol 2001; 25: 1268-1276.
40. Franco V, Florena A, Stella M, et al. Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer 2001; 91: 294-301.